Alexandria Co. For Pharmaceuticals & Chemical Industries (EGX: AXPH)
Egypt
· Delayed Price · Currency is EGP 394.49
0.00 (0.00%)
At close: Feb 2, 2025
EGX:AXPH Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | 1,768 | 1,484 | 1,100 | 1,104 | 1,015 | Upgrade
|
| Other Revenue | - | - | 0 | - | 9.87 | Upgrade
|
| Revenue | 1,768 | 1,484 | 1,100 | 1,104 | 1,025 | Upgrade
|
| Revenue Growth (YoY) | 19.12% | 34.94% | -0.38% | 7.75% | 23.61% | Upgrade
|
| Cost of Revenue | 1,373 | 1,223 | 876.78 | 841.45 | 703.59 | Upgrade
|
| Gross Profit | 395.18 | 260.89 | 223.24 | 262.8 | 321.23 | Upgrade
|
| Selling, General & Admin | 89.03 | 83.52 | 75.65 | 93.71 | 86.44 | Upgrade
|
| Other Operating Expenses | 38.66 | 22.44 | 13.05 | 14.98 | 13.09 | Upgrade
|
| Operating Expenses | 127.69 | 105.96 | 88.7 | 108.69 | 99.53 | Upgrade
|
| Operating Income | 267.49 | 154.92 | 134.54 | 154.11 | 221.7 | Upgrade
|
| Interest & Investment Income | 13.52 | 5.52 | 5.55 | 2.82 | 2.82 | Upgrade
|
| Currency Exchange Gain (Loss) | 8.03 | 11.57 | 4.4 | -0.24 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 0 | - | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 289.04 | 172.02 | 144.49 | 156.69 | 224.61 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.56 | 1.03 | - | 0.4 | 0.49 | Upgrade
|
| Other Unusual Items | -7.57 | -8.1 | -0.99 | -5.5 | -4.29 | Upgrade
|
| Pretax Income | 282.03 | 164.95 | 143.5 | 151.59 | 220.82 | Upgrade
|
| Income Tax Expense | 65.35 | 38.52 | 26.08 | 34.59 | 50.77 | Upgrade
|
| Net Income | 216.68 | 126.43 | 117.42 | 117 | 170.05 | Upgrade
|
| Net Income to Common | 216.68 | 126.43 | 117.42 | 117 | 170.05 | Upgrade
|
| Net Income Growth | 71.39% | 7.67% | 0.36% | -31.20% | 50.68% | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 6 | Upgrade
|
| Shares Change (YoY) | - | - | - | -15.35% | -5.58% | Upgrade
|
| EPS (Basic) | 43.34 | 25.29 | 23.48 | 23.40 | 28.79 | Upgrade
|
| EPS (Diluted) | 43.34 | 25.29 | 23.48 | 23.40 | 28.79 | Upgrade
|
| EPS Growth | 71.39% | 7.67% | 0.36% | -18.72% | 59.59% | Upgrade
|
| Free Cash Flow | 127.41 | 7.09 | 160.9 | -20.57 | 68.57 | Upgrade
|
| Free Cash Flow Per Share | 25.48 | 1.42 | 32.18 | -4.11 | 11.61 | Upgrade
|
| Dividend Per Share | 30.000 | 13.000 | - | 10.000 | 15.500 | Upgrade
|
| Dividend Growth | 130.77% | - | - | -35.48% | 38.39% | Upgrade
|
| Gross Margin | 22.35% | 17.58% | 20.29% | 23.80% | 31.34% | Upgrade
|
| Operating Margin | 15.13% | 10.44% | 12.23% | 13.96% | 21.63% | Upgrade
|
| Profit Margin | 12.26% | 8.52% | 10.67% | 10.60% | 16.59% | Upgrade
|
| Free Cash Flow Margin | 7.21% | 0.48% | 14.63% | -1.86% | 6.69% | Upgrade
|
| EBITDA | 305.05 | 182.92 | 157.73 | 177.74 | 244.15 | Upgrade
|
| EBITDA Margin | 17.25% | 12.32% | 14.34% | 16.10% | 23.82% | Upgrade
|
| D&A For EBITDA | 37.56 | 28 | 23.18 | 23.63 | 22.45 | Upgrade
|
| EBIT | 267.49 | 154.92 | 134.54 | 154.11 | 221.7 | Upgrade
|
| EBIT Margin | 15.13% | 10.44% | 12.23% | 13.96% | 21.63% | Upgrade
|
| Effective Tax Rate | 23.17% | 23.35% | 18.17% | 22.82% | 22.99% | Upgrade
|
| Revenue as Reported | 1,777 | 1,486 | 1,101 | 1,111 | 1,025 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.